Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy.

Sci Rep · 2025 · PMC12508025 · PMID 41062634

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

At the time of writing, preliminary results from the phase III KEYNOTE-689 trial have been announced, marking the first demonstration of a significant event-free survival benefit (and a positive trend in OS) for perioperative immunotherapy in HNSCC.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.